ARTICLE | Deals
Lonza ‘cocoons’ give academics route to scale autologous cell therapies
March 9, 2020 11:49 PM UTC
Updated on Mar 10, 2020 at 2:35 AM UTC
A deal granting academics access to Lonza’s automated manufacturing pods could ramp up patient access to next-generation autologous cell therapies. In the long term, widespread adoption of such decentralized patient-scale technologies could help redefine modalities like CAR T cells as procedures instead of drugs.
On Monday, Lonza Group Ltd. (SIX:LONN) announced a research collaboration with Stanford University School of Medicine, Fred Hutchinson Cancer Research Center and Parker Institute for Cancer Immunotherapy...